Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer
Introduction
Multiple genetic events are involved in carcinogenesis in the oral region, including activation of oncogenes and inactivation of tumor suppressor genes.1, 2 Recently, factors related to angiogenesis and thrombosis have been also implicated in the predisposition for development and advancement of oral squamous cell carcinoma.1, 3, 4, 5 A factor related to both thrombophilia and other types of cancer is plasminogen activator inhibitor-1 (PAI-1).6, 7, 8, 9, 10, 11, 12, 13
PAI-1 controls the activation of plasmin by regulating the activities of tissue plasminogen activators.9 Tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA) convert the inactive proenzyme plasminogen to its active form plasmin.9 Plasmin plays an important role in fibrinolysis as well as in the zymogen activation of matrix metalloproteinases (MMPs).9, 14 The MMPs constitute a large family of proteases, which have pivotal roles in development and tissue remodeling by degrading the major components of the extracellular proteins, including type I collagen.1, 9, 14 In oral cancer, MMP-2 and MMP-9 are produced by tumor cells at variable degrees.1, 15
In addition to its role in extracellular matrix proteolysis, PAI-1 is also involved in cellular adhesion and migration through its binding to vitronectin or integrins.9 Integrins are cation-dependent cell adhesion molecules, which compete with PAI-1 for binding to the extracellular matrix glycoprotein vitronectin.9 By mediating cell–cell and cell–matrix interactions, integrins play an important role in the maintenance of tissue integrity and in the regulation of cell proliferation, growth, differentiation, and migration.1, 9 Expression of integrins varies in different tumor types and these molecules are implicated in tumor progression and metastasis.1 Excess of PAI-1 leads to hypofibrinolysis, down regulation of MMPs and decreased cellular adhesion.9
A deletion/insertion polymorphism (4G/5G) in the promoter region of the PAI-1 gene interferes with its transcription regulation.7 The 4G allele binds only an activator, while the 5G allele binds a repressor as well as an activator, therefore results in reduced transcription of PAI-1.16 It follows that the 5G variant is associated with reduced inhibition of the plasminogen activators and, consequently, increased plasminogen conversion to plasmin, increased activation of MMPs and decreased adhesive strength of cells for their substratum.7, 8, 16 The 4G/5G allele frequencies range in various populations from 31/69% to 63/37%, respectively.6, 17, 18, 19, 20, 21 Homozygosity of the 4G allele is considered to be a risk factor for deep vein thrombosis, myocardial infarction and high rate of miscarriage during pregnancy.6, 7, 8
Significantly higher levels of PAI-1 than in normal tissue have been reported in colorectal cancer, glioma and breast cancer, and some studies have found significant association of the 4G allele with increased risk for these types of cancer.10, 11, 22, 23, 24 Nevertheless, a strong association of the 5G allele with uPA/PAI-1 complex accumulation inside breast cancer cells was observed in conjunction with a less aggressive, better-differentiated tumor phenotype.22, 23
Increased PAI-1 expression has been correlated with advancement of oral squamous cell carcinoma, poor prognosis and tumor relapse.25, 26, 27 In this light, it would be interesting to investigate whether the 4G/5G polymorphism in the promoter area of the PAI-1 gene is associated with increased risk for oral cancer. In order to examine the effect of 4G/5G in Europeans, we evaluated the polymorphism in DNA samples of 104 patients with oral cancer and 106 healthy controls of comparable age and sex.
Section snippets
Material and methods
The subjects under study included 210 unrelated individuals of Greek and German origin, namely 104 patients with oral squamous cell carcinoma and 106 healthy blood donors (controls representing the general population) with matched ethnicity, sex and age. The patients had an age range of 40–83 years (52.1 ± 7.2 years, median 58 years) and were mostly men (N = 94). The controls were selected from a larger series of healthy blood donors on a basis of comparable age (range 40–82; 51.5 ± 5.5 years,
Discussion
Plasminogen activators and their inhibitors, such as PAI-1, are thought to play an important role in oncogenesis and metastasis. High levels of PAI-1 have been observed in several types of cancer, including oral squamous cell carcinoma.10, 11, 24, 25, 26, 27 A common 4G allele in the promoter region results in increased expression of the PAI-1 gene and has been associated with both thrombophilia and several types of cancer.6, 7, 8, 10, 11, 16, 23 Based on this knowledge, and in view of recent
Acknowledgements
This work was supported in part by EPEAEK “Pythagoras” grant 70/3/7391 of the Greek Secretariat of Research and Technology to E.V.
References (30)
- et al.
Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells
Oral Oncol
(2000) - et al.
A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis
Thromb Res
(1996) - et al.
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis
Cancer Lett
(2003) - et al.
Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms
J Vasc Surg
(2000) - et al.
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal neoplastic tissues of patients with squamous cell cancer of the oral cavity-clinical relevance and prognostic value
Craniomaxillofac Surg
(2005) Molecular pathogenesis of oral carcinoma
J Clin Pathol
(2000)- et al.
Genome-wide profiling of oral squamous cell carcinoma
J Pathol
(2004) - et al.
Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population
Cancer Res
(2001) - et al.
Are factor V and prothrombin mutations associated with increased risk of oral cancer?
Anticancer Res
(2005) - et al.
Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
Proc Natl Acad Sci USA
(1995)
The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia
Clin Appl Thromb Hem
The urokinase-type plasminogen activator system in cancer metastasis: a review
Int J Cancer
Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer
J Exp Clin Cancer Res
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth
Oncogene
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer
Thromb Haemost
Cited by (56)
PAI-1 mediates the TGF-Β1EGF-induced scatter response in transformed human keratinocytes
2010, Journal of Investigative DermatologyGene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer
2009, Oral OncologyCitation Excerpt :Therefore, a single control group, consisting of both ethnicities, was used for all further analyses. All genotype frequencies in the combined control group were compatible with the Hardy–Weinberg equilibrium, with the exception of GPIα.10–18 The genotype frequencies of all studied polymorphisms are summarised in Table 2.
A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma
2008, European Journal of Surgical OncologyEvolving role of uPA/uPAR system in human cancers
2008, Cancer Treatment ReviewsROLE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) IN CANCER STEM CELLS
2022, World Cancer Research Journal